InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue
November 21, 2022
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis (“RA”), designated as SPU-21, in human synovial tissue surrounding joints and tendons. The three-month study will assess the binding affinity […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Milestone in IND-Enabling Study of Time-Released Ketamine Formulation
November 11, 2022
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced initial dosing in its IND-enabling study of SP-26, its novel time-released, topical formulation of ketamine. According to the update, the objective of this safety evaluation study, conducted by Experimur (a Frontage Company), is to evaluate the […]
Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease
November 4, 2022
Silo recently extended Columbia University agreement to continue research for novel therapeutics to treat Alzheimer’s disease and stress-induced anxiety disorder Preclinical studies demonstrate Silo’s jointly-developed Z-pod(TM) delivery technology holds and distributes therapeutics in a time-released manner to potentially provide targeted delivery Additional treatment research includes funding for the UCSF Translational Psychedelic Program to study effects […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Confident in Preclinical Work on Its Novel Ketamine Formulation
November 3, 2022
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, is focused on fusing traditional therapeutics with psychedelic research to provide novel treatments for numerous indications, including post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, and other rare neurological disorders. “Silo Pharma is currently developing ketamine treatments for fibromyalgia – a chronic disease that causes pain throughout the […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Present at Largest Gathering in Psychedelic Medicine Sector
October 26, 2022
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its VP of R&D, James Kuo, M.D. M.B.A, will speak as a panelist at Wonderland: Miami, the largest business gathering in the psychedelic medicine sector. According to the update, Silo Pharma is a sponsor of […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Distinctive with Ground-Breaking Research, Commitment to Developing Innovative Solutions
October 24, 2022
Silo Pharma (NASDAQ: SILO) recently uplisted to the NASDAQ after the exciting progress it made over the last year. “Silo Pharma announced that it had successfully priced its fully underwritten initial public offering, raising gross proceeds of $5 million through the sale of one million shares of common stock,” reads a recent article. “Originally founded […]
Silo Pharma Inc.’s (NASDAQ: SILO) Novel Ketamine Formulation Undergoing Safety Evaluation, Pursuing Regulatory Pathway
Ketamine used for decades in large doses for surgical anesthesia, low-dose treatments currently prescribed for pain relief, sedation, and treatment-resistant depression Silo’s time-released ketamine formulation SP-26 currently undergoing safety evaluation, study to uncover maximum tolerated dosing data for future trials SP-26 previously reported positive results in reducing neuropathic nerve pain Silo preparing FDA Pre-Investigational New […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Data Supporting SPC-14’s Therapeutic Potential for Alzheimer’s
October 20, 2022
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer’s disease, as demonstrated in a mouse model. According to the announcement, the research was conducted as part of a sponsored agreement with Columbia […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Agreement with Columbia University to Extend Research Pact
October 18, 2022
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has entered into an agreement with Columbia University to extend its current research partnership efforts. The agreement outlines certain assets that are currently under development regarding the work of associate professor of clinical Neurobiology Dr. Christine Ann Denny […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Initiates Safety Evaluation Study of Its Novel Time-Released Ketamine Formulation
October 10, 2022
Silo Pharma (NASDAQ: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company today announced that it has initiated a preclinical toxicity study of its novel time-released, dosage controlled formulation of ketamine, designated as SP-26, for the treatment of fibromyalgia. “We are working closely with our joint venture […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Participate at Upcoming Dawson James Small Cap Growth Conference
October 6, 2022
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is scheduled to participate in the 7th annual Dawson James Small Cap Growth Conference. Silo Pharma CEO Eric Weisblum will present at the event, which is scheduled for Oct. 12, 2022, in Jupiter, Florida. Weisblum’s presentation will include […]
Silo Pharma Inc. (NASDAQ: SILO) Successfully Uplists, Commences Trading on the Nasdaq Market
October 5, 2022
Silo Pharma, Inc recently uplisted to the Nasdaq Capital Market, raising gross proceeds of $5 million The biopharmaceutical company has sought to merge traditional therapeutics and psychedelic research, entering into a series of joint ventures with leading medical universities to carry out research into the field Meanwhile, psychedelics are gaining increasing favour within the United […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Preparing for Ketamine Tech FDA Pre-Investigational New Drug Package
October 3, 2022
Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, is collaborating with Premier Consulting to prepare a pre-investigational new drug (“IND”) package and meeting request with the United States Food and Drug Administration (FDA) for SPC-26, the company’s novel topical formulation of ketamine for the treatment of […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures $5.75M in Underwritten Public Offering
September 30, 2022
Silo Pharma (NASDAQ: SILO) (formerly OTCQB: SILO) is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research. The company today announced the closing of its underwritten public offering of 1,150,000 shares of its common stock, which included the full exercise of the underwriters’ over-allotment option to purchase 150,000 additional shares of […]
InvestorNewsBreaks – Cerberus Cyber Sentinel Corp. (NASDAQ: CISO) Stands Distinct with Integrated Approach to Reduce Noise, Bridge Silos
September 29, 2022
Cerberus Sentinel (NASDAQ: CISO) is helping organizations create a culture of security, allowing them to quantify, define and capture a return on investment from information technology and cybersecurity spending. “Cerberus Sentinel has established a reputation for its integrated approach to reduce noise and bridge common silos that often limit the effectiveness of cybersecurity programs. The […]
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Uplisting to Nasdaq Capital Market, Pricing of $5M Public Offering
September 27, 2022
Silo Pharma (NASDAQ: SILO) (formerly OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced pricing of an underwritten public offering of 1,000,000 shares of its common stock at a price to the public of $5.00 per share. Silo Pharma expects $5,000,000 in gross proceeds from the offering […]
InvestorNewsBreaks – Silo Pharma Inc. (SILOD) Implements Reverse Stock Split in Preparation for Nasdaq Uplisting
September 15, 2022
Silo Pharma (OTCQB: SILOD), a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it will effect a 1-for-50 reverse split of its common stock. Effective at the open of business on Thursday, Sept. 15, 2022, the reverse stock split is in preparation for the planned listing of the company’s […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marking Industry’s First-Ever Entry of Novel Psilocybin Analog into Clinical Development
September 14, 2022
Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is making significant headway with its flagship deuterated psilocybin analog, CYB003. “CYB003 has the potential to effectively treat alcohol use disorder (‘AUD’) and major depressive disorder (‘MDD’). The substance is designed to achieve […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) on Leading Edge of Psilocybin Research
September 8, 2022
Cybin (NYSE American: CYBN) (NEO: CYBN) is a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions. The company is on the leading edge of a transformation that has seen the status of psilocybin evolve as a result of mounting public acceptance and growing evidence that the substance delivers […]
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD
August 31, 2022
A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybin These results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybin After receiving FDA approval, the company is moving forward with a first-in-human clinical trial evaluating CYB003 A new study published in JAMA Psychiatry offers hope […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Fusing Traditional Therapeutics with Psychedelic Research
August 25, 2022
Silo Pharma (OTCQB: SILO) recently reported that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients. The psilocybin was administered “as part of a scientific research agreement (‘SRA’) entered with Silo in June 2021 to ‘determine the effects of psilocybin on inflammatory markers of patients […]
Silo Pharma Inc. (SILO): Promising Psylocibin Study Ongoing with UCSF
August 17, 2022
Company entered scientific research agreement with UCSF in June 2021 to study psilocybin effects on various inflammatory conditions Silo Pharma (OTCQB: SILO), recently announced that the University of California San Francisco (“UCSF”) had successfully administered psilocybin to a test group of Parkinson’s disease patients as part of a scientific research agreement (“SRA”) entered with Silo […]
InvestorNewsBreaks – Silo Pharma Inc.’s (SILO) Ketamine Study Generates ‘Extremely Promising’ Data
August 12, 2022
Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company, recently completed an animal study of its ketamine formulation, showing nerve pain reduction when administered using a patented delivery system developed in partnership with Zylo Therapeutics. “Results from the small animal study produced positive endpoint results, demonstrating that Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Reports Positive Results from Research on Novel Liposomes
August 4, 2022
Silo Pharma (OTCQB: SILO) recently announced it had produced an initial batch of SPU-21 liposomes for a rheumatoid arthritis study conducted by Frontage Laboratories, a contract research organization (“CRO”). “Recent research by the company revealed that SPU-21 liposomes have the ability to target inflamed epithelium, suggesting they can be used to target drug delivery. Further, […]
Silo Pharma Inc.’s (SILO) Ketamine Study Produces Positive Endpoint Results, Suggests Topical Formulation Reduces Neuropathic Nerve Pain
August 3, 2022
Silo recently completed ketamine study showing neuropathic nerve pain reduction when administered with patented, partnered delivery system Results of study demonstrated Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, mechanical hyperalgesia reduced on day seven at the pre-dose time point Ketamine typically used to induce and maintain […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Reports Positive Results from Study Evaluating Topically Administered Ketamine Formulation
July 27, 2022
Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company, has reported that its recent animal study evaluating topically administered ketamine reached a positive end point: using SILO’s selected formulation and partnered, patented delivery system, the study indicated reversal of allodynia and hyperalgesia. According to the announcements, the proprietary formulation reduced mechanical allodynia and hyperalgesia at […]
Silo Pharma Inc. (SILO) Produced Initial Liposome Batch for Rheumatoid Arthritis Study
July 25, 2022
Silo Pharma produced initial batch of SPU-21 liposomes for rheumatoid arthritis study conducted by CRO Frontage Laboratories Recent company research revealed SPU-21 liposomes can target inflamed epithelium, suggesting use for targeted drug delivery SPU-21 can be used for development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis Company recently announced positive results in […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO), UMB Collaborating on Potentially Significant Homing-Peptide Technology
July 22, 2022
Silo Pharma (OTCQB: SILO) earlier this year extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and blood vessels). “Silo’s partnership with UMB focuses on peptides used for investigating and treating the arthritogenic […]
Homing Peptides: Silo Pharma Inc. (SILO) Targets ADRs
July 13, 2022
Silo’s partnership with UMB could yield therapeutics that limit side effects through precisely targeted delivery On February 3, 2022, Silo Pharma (OTCQB: SILO) extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Announces Positive Results of New Study
July 12, 2022
Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company, today announced that its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method. “The successful results of our study show that the subcutaneous route of liposomal administration is well-suited for use in targeted drug delivery of anti-arthritic […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Bringing Hope, Possible Therapeutic to Alzheimer’s Patients
July 8, 2022
Silo Pharma (OTCQB: SILO) is committed to serving patients, families and caregivers worldwide struggling with Alzheimer’s Disease (“AD”). Last year, the company entered into a sponsored research agreement (“SRA”) with Columbia University to investigate and advance psychedelic therapeutics for AD. Silo Pharma CEO Eric Weisblum expressed encouragement on partnering with Columbia University and Dr. Christine […]
Silo Pharma Inc. (SILO) Takes Aim at Alzheimer’s Disease
June 27, 2022
In October 2021, Silo Pharma (OTCQB: SILO) entered into a sponsored research agreement (“SRA”) with Columbia University to investigate and advance psychedelic therapeutics for Alzheimer’s Disease (“AD”). SRA’s grant Silo access to world-class research facilities to sponsor potential life-changing research while offering Silo licensing opportunities for groundbreaking psychedelic remedies. Columbia University Irving Medical Center (“CUIMC”), […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Announces Expansion of License Agreement and Patent Portfolio
June 23, 2022
Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that it has expanded its commercial evaluation license agreement (“CELA”) with the University of Maryland Baltimore (“UMB”) for its next-generation liposomal peptide targeting autoimmune diseases. “We are delighted to expand our partnership with UMB. Pre-clinical testing […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Committed to Psilocybin, Anti-Inflammatory Research
June 13, 2022
Silo Pharma (OTCQB: SILO) still believes in medicinal mushrooms despite the fact that they are currently outlawed by the U.S. government (though legal in Oregon and decriminalized in various cities and states). Recently, the company announced that the Translational Psychedelic Research (“TrPR”) Program at the University of California San Francisco (“UCSF”) had successfully dosed [with […]
Silo Pharma Inc. (SILO) Focuses on Psilocybin’s Anti-Inflammatory Properties
May 31, 2022
On May 19, 2022, Silo Pharma (OTCQB: SILO) announced that The Translational Psychedelic Research (“TrPR”) Program at UCSF (University of California San Francisco) had “successfully dosed [with psilocybin] patients suffering from Parkinson’s disease.” TrPR connects researchers and medical professionals studying how psychedelics, including psilocybin, ketamine, etc., affect brain functions and other organ systems. Silo Pharma […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Bringing Hope to Patients Suffering from Alzheimer’s and Potentially Other Ailments
May 23, 2022
Silo Pharma (OTCQB: SILO) is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s and Parkinson’s disease. With more than 80% of Parkinson’s patients and 75% of Alzheimer’s patients experiencing dysphagia, difficulty or complete inability to swallow, last year, SILO entered into a joint venture with Zylö Therapeutics. Under the collaboration, the […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Announces Milestone in Psilocybin Study on Parkinson’s Patients
May 19, 2022
Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that, in conjunction with the University of California San Francisco (“UCSF”), researchers have successfully dosed patients suffering from Parkinson’s disease. As part of the study, researchers are collecting blood samples to determine the effects of psilocybin […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) CEO Featured in Bell2Bell Podcast Episode
May 18, 2022
Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, and its founder and CEO Eric Weisblum are the center of attention in the most recent episode of the Bell2Bell Podcast. The Bell2Bell Podcast is designed to provide informative updates and exclusive interviews with executives operating in fast-moving […]
IBN (InvestorBrandNetwork) Announces Latest Episode of The Bell2Bell Podcast featuring Eric Weisblum, CEO of Silo Pharma Inc.
LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) — via InvestorWire — IBN (InvestorBrandNetwork), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates […]
Silo Pharma Inc. (SILO) Spotlight: Ketamine
May 11, 2022
Ketamine shows promise in treating Alzheimer’s Disease, Parkinson’s Disease as well as depression, suicide ideation and more In 2021, Silo Pharma (OTCQB: SILO) entered into a joint venture with Zylö Therapeutics to “explore the clinical development of ketamine using ZTI’s Z-pod (transdermal) technology.” This innovative technology allows Silo, an early-stage biopharmaceutical company, to develop a […]